share_log

8-K: Current report

8-K: Current report

8-K：重大事件
美股SEC公告 ·  08/16 17:03

Moomoo AI 已提取核心訊息

On August 15, 2024, Conduit Pharmaceuticals Inc. received two deficiency notices from The Nasdaq Stock Market LLC. The first notice indicated that the company's common stock did not meet the Nasdaq's minimum market value of publicly held shares requirement of $15 million over the past 30 consecutive business days. The second notice stated that the company also failed to comply with the minimum market value of listed securities requirement of $50 million. Conduit Pharmaceuticals has been given 180 days, until February 11, 2025, to regain compliance with both requirements. If the company fails to meet these requirements within the given timeframe, its securities may be delisted from Nasdaq. The company may also consider transferring its securities to The Nasdaq Capital Market if it meets the continued listing requirements there. In a separate event, Conduit Pharmaceuticals became aware of undisclosed share dispositions by a director through a subsidiary and a third-party pledge arrangement involving approximately 31% of its outstanding common stock. In response, the company has formed two independent committees to review these matters and determine necessary actions.
On August 15, 2024, Conduit Pharmaceuticals Inc. received two deficiency notices from The Nasdaq Stock Market LLC. The first notice indicated that the company's common stock did not meet the Nasdaq's minimum market value of publicly held shares requirement of $15 million over the past 30 consecutive business days. The second notice stated that the company also failed to comply with the minimum market value of listed securities requirement of $50 million. Conduit Pharmaceuticals has been given 180 days, until February 11, 2025, to regain compliance with both requirements. If the company fails to meet these requirements within the given timeframe, its securities may be delisted from Nasdaq. The company may also consider transferring its securities to The Nasdaq Capital Market if it meets the continued listing requirements there. In a separate event, Conduit Pharmaceuticals became aware of undisclosed share dispositions by a director through a subsidiary and a third-party pledge arrangement involving approximately 31% of its outstanding common stock. In response, the company has formed two independent committees to review these matters and determine necessary actions.
2024年8月15日，Conduit Pharmaceuticals Inc.從納斯達克證券交易所收到了兩封違規通知。第一封通知指出，該公司的普通股未達到納斯達克公開持股要求的最低市值1500萬美元，且在過去連續30個營業日中均未達標。第二封通知指出，該公司還未達到$5000萬的上市證券最低市值要求。Conduit Pharmaceuticals被要求在180天內，即2025年2月11日之前恢復符合這兩個要求。如果該公司未能在給定的時間內達到這些要求，其證券可能會被納斯達克除牌。該公司也可以考慮將其證券轉移到納斯達克資本市場，如果它在那裏符合繼續上市的要求。在另一件事中，Conduit Pharmaceuticals發現一位董事通過子公司和第三方抵押安排未公開出售約佔其流通普通股31%的股份。作爲回應，該公司成立了兩個獨立委員會審查這些事項並確定必要的行動。
2024年8月15日，Conduit Pharmaceuticals Inc.從納斯達克證券交易所收到了兩封違規通知。第一封通知指出，該公司的普通股未達到納斯達克公開持股要求的最低市值1500萬美元，且在過去連續30個營業日中均未達標。第二封通知指出，該公司還未達到$5000萬的上市證券最低市值要求。Conduit Pharmaceuticals被要求在180天內，即2025年2月11日之前恢復符合這兩個要求。如果該公司未能在給定的時間內達到這些要求，其證券可能會被納斯達克除牌。該公司也可以考慮將其證券轉移到納斯達克資本市場，如果它在那裏符合繼續上市的要求。在另一件事中，Conduit Pharmaceuticals發現一位董事通過子公司和第三方抵押安排未公開出售約佔其流通普通股31%的股份。作爲回應，該公司成立了兩個獨立委員會審查這些事項並確定必要的行動。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間